Clinical trial startup ClinOne is collaborating with continuous health monitoring (CHM) firm BioIntelliSense to incorporate data generated from the latter’s FDA-cleared BioSticker single-use device to ClinOne’s ClinTrialConnect patient portal platform.
For context, ClinOne partners with health systems and pharmaceutical companies, and the ClinTrialConnect platform is designed to help patients navigate the complex clinical trial participation process with features like clinical trial education, an appointment calendar, and secure communication between researchers and patients.
Through the tie-up, ClinOne will enable researchers to incorporate real-time data on patients’ vitals into trials, which can improve the efficacy of treatments. Adding the BioSticker device to the ClinTrialConnect platform provides researchers with 30 days of continuous monitoring of participants’ vital sign data, including respiratory rate at rest, heart rate at rest, and skin temperature.
This can be a huge value add to clinical research, considering vital measurements are key to evaluating treatment efficacy, per Pharmaceutical Outsourcing: Researchers can leverage the continuous data gathered by the BioSticker device to correlate multiple vital signs and analyze patients’ responses to certain treatments.
And considering ClinOne’s platform makes it easier for consumers to participate, it could result in a higher retention rate of participants, giving ClinOne a boost in the eyes of potential partners, considering 86% of clinical trials fail to hit recruitment targets within their given time frames.
The addition of the BioSticker device to ClinOne’s platform could also speed up drug discovery, making it prime candidate for pharma tie-ups. Implementing remote monitoring can improve the efficiency and cost-effectiveness of clinical trials by limiting the amount of time needed to capture information from participants to determine a treatment’s efficacy and side effects.
This can have huge implications on drug discovery by expediting research and limiting development costs: Pharmaceutical companies spend $2.6 billion to put a prescription drug through testing and trials, but leveraging real-time data on how participants are reacting to novel drugs could help speed up research — which is likely top of mind for pharmaceutical companies, given it takes an average of seven years to bring a drug to market.
Hence, we think the collaboration between ClinOne and BioIntelliSense could make the clinical trial startup a promising candidate for pharma firms looking to cut down on the time and associated costs of bringing a drug to market.